Here, we use liquid chromatography/mass spectrometry (LC/MS) analyses on Drosophila CRC tumour models to identify multiple metabolites in the glucuronidation pathway—a toxin clearance pathway that impacts most drugs—as upregulated in trametinib-resistant RAS/APC/P53 (“RAP”) tumours compared to trametinib-sensitive RasG12V single mutant tumours. Here, TP53 is linked to neoplasm.